Aragen Life Sciences files draft papers with SEBI; eyes ₹800-cr via fresh issue
An offer for sale (OFS) of 2.73 crore equity shares will be made by selling shareholders, per the draft red herring prospectus (DRHP) filed Wednesday
Indian contract research, development and manufacturing organisation (CRDMO) Aragen Life Sciences Ltd has submitted draft registration papers to the capital markets regulator SEBI, seeking to raise ₹800 crore via an initial public offering (IPO). The draft red herring prospectus (DRHP) filed on Wednesday also includes an offer for sale (OFS) of 2.73 crore equity shares by existing shareholders, comprising promoters and investors like Goldman Sachs Capital Holdings.
The funds raised from the fresh IPO will be used to repay and prepay existing borrowings, invest in capital expenditure for new equipment and machinery at Aragen Life Sciences' Hyderabad facilities, and support capital expenditure at its Bengaluru material subsidiary Aragen Biologics Pvt Ltd. The company, established in 2000, is a full-service CRDMO catering to global innovators and emerging firms across the life sciences sector, with services ranging from contract discovery and pre-clinical research to contract development and manufacturing for small molecules and biologics.
In the fiscal year 2026, Aragen Life Sciences catered to 591 global customers across major markets like the US, Europe, Japan, India, and other Asia-Pacific regions. Among its clientele are major pharma companies, large and mid-sized pharmaceutical firms, biotechnology companies, and players in animal health, agrochemicals, and specialty chemicals.
The company employs 4,362 individuals as of March 31, 2026. The IPO is being managed by book-running lead managers including Axis Capital, Citigroup Global Markets India, Goldman Sachs (India) Securities Pvt Ltd, and JM Financial.
Written by urgent.news from Hindu BusinessLine's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
